预约演示
更新于：2025-05-16
Lusutrombopag
芦曲泊帕
更新于：2025-05-16
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2015-09-28), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国) |
登录后查看时间轴
结构/序列
分子式C29H32Cl2N2O5S |
InChIKeyNOZIJMHMKORZBA-KJCUYJGMSA-N |
CAS号1110766-97-6 |
关联
28
项与 芦曲泊帕 相关的临床试验ChiCTR2400084748
Clinical study on the efficacy and safety of lusutrombopag in the treatment of thrombocytopenia in patients undergoing liver resection after conversion therapy for liver cancer
NCT06426043
An Exploratory Study on the Efficacy and Safety of Lusutrombopag in the Treatment of Recurrent/Refractory/Intolerable NSAA
ChiCTR2400084012
Efficacy and safety of lusutrombopag in the treatment of patients with non-severe aplastic anemia (NSAA).
100 项与 芦曲泊帕 相关的临床结果
登录后查看更多信息
100 项与 芦曲泊帕 相关的转化医学
登录后查看更多信息
100 项与 芦曲泊帕 相关的专利（医药）
登录后查看更多信息
107
项与 芦曲泊帕 相关的文献（医药）2025-01-01JGH Open
Evaluation of the Efficacy of Lusutrombopag for Chronic Liver Disease Based on Pre‐Treatment Platelet Counts: A Retrospective Multicenter Study
Article
作者: Suga, Takayoshi ; Takakusagi, Satoshi ; Hatanaka, Takeshi ; Saito, Shuichi ; Kakizaki, Satoru ; Ueno, Takashi ; Takizawa, Daichi ; Fukuchi, Toru ; Iizuka, Keisuke ; Yamazaki, Yuichi ; Tojima, Hiroki ; Arai, Hirotaka ; Naganuma, Atsushi ; Uraoka, Toshio
ABSTRACT:
Background:
Oral thrombopoietin receptor agonists are used to treat thrombocytopenia in patients with chronic liver disease who are scheduled for invasive procedures. The efficacy of lusutrombopag based on the pretreatment platelet count was investigated.
Methods:
Patients treated at nine hospitals from December 2015 to December 2023 were included. Efficacy was assessed by comparing the proportion of patients achieving a platelet count ≥ 50 000/μL and the change in platelet count.
Results:
Seventy patients were eligible for evaluation. Patients with a pretreatment platelet count < 40 000/μL had a significantly lower rate of achieving a platelet count of ≥ 50 000/μL than those with a pretreatment count of 40 000–50 000/μL (62.5% vs. 84.2%, p = 0.038); however, there was no significant difference in the change in platelet count (25 700 vs. 24 400/μL, p = 0.972). Patients with viral‐related cirrhosis showed a significantly greater change in platelet count than the others (29 100 vs. 19 200/μL, p = 0.012). For patients receiving multiple lusutrombopag treatments, the change in platelet count was significantly lower in the second treatment than in the first treatment (26 900 vs. 20 800/μL, p = 0.041). The main adverse event observed was thrombosis (2.9%).
Discussion:
Lusutrombopag increases platelet count regardless of pretreatment levels, but efficacy, defined as achieving a platelet count of ≥ 50 000/μL, may be insufficient in patients with a pretreatment platelet count < 40 000/μL. Additionally, patients with non‐viral liver disease responded less well to treatment compared to those with viral liver disease. Therefore, treatment strategies should be tailored based on pretreatment platelet counts and the etiology of liver disease.
2025-01-01INTERNAL MEDICINE
Usefulness of Repeated Lusutrombopag Administration in Clinical Practice and its Correlation with the Simulation Software-Predicted Platelet Count: A Multicenter Study
Article
作者: Morishita, Asahiro ; Tani, Joji ; Kurosaki, Masayuki ; Tamada, Takashi ; Ogawa, Chikara ; Ochi, Hironori ; Manabe, Takushi ; Yoshioka, Naoki ; Nakahara, Mai ; Takaki, Shintaro ; Takuma, Kei ; Nakamura, Shinichiro ; Fujii, Hideki ; Kobara, Hideki ; Fujita, Koji ; Tsuji, Keiji ; Akahane, Takehiro ; Izumi, Namiki ; Oura, Kyoko ; Mori, Nami ; Arai, Hirotaka ; Tadokoro, Tomoko
Objective Lusutrombopag is recommended for severe thrombocytopenia (<5.0×104/μL) in patients with chronic liver disease who are scheduled to undergo invasive procedures. However, reports on the efficacy of repeated lusutrombopag dosing are scarce. It is also not known whether lusutrombopag causes the platelet count to exceed 5.0×104/μL. We evaluated the efficacy of repeated lusutrombopag dosing and the efficacy of the platelet prediction simulation software program. Methods We evaluated the number of platelet elevations according to the number of lusutrombopag administrations. We also evaluated the correlation between the highest software-predicted platelet count and the platelet count measured in actual clinical practice. Patients This retrospective study included 236 patients treated with lusutrombopag at 11 medical institutions in Japan. Results The platelet count increased with the number of lusutrombopag administrations (1, 2, 3, 4, >4) in all groups, and no significant difference was found among the groups (p = 0.169). In all groups, the platelet counts reached their highest levels at 8-14 days after treatment with lusutrombopag (p = 0.243). There was a correlation between the highest software-predicted platelet count and the platelet count measured in actual clinical practice in all dose frequency groups; however, the correlation was the strongest in the one-dose group (r = 0.74, p <0.0001). Conclusion Frequent lusutrombopag administration is therefore both effective and safe, and a platelet prediction simulation software program is thus considered to be useful in practice.
2024-10-20Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
[Clinical research progress of lusutrombopag for the treatment of thrombocytopenia in chronic liver disease].
Review
作者: Zhang, J Y ; Xu, Z ; Wang, F S
Thrombocytopenia is one of the common complications with the hematologic system in patients with chronic liver disease, which often causes poor quality of life and high risk of bleeding, thereby affecting their diagnosis, treatment, and prognosis. Platelet transfusion can improve the patient's declining platelet count to a certain extent, but it has problems such as high price and being easy to cause immune rejection. Thrombopoietin (TPO), as an important cytokine that affects platelet production, can bind to TPO receptors and activate megakaryocytes to produce platelets. Lusutrombopag is a newly developed small-molecule TPO receptor agonist that can induce bone marrow progenitor cells to differentiate into megakaryocytes and increase platelet production, posing characteristics of oral convenience, safety and effectiveness; thus, it has been used in many countries and regions for the treatment of patients with chronic liver diseases concurrent with thrombocytopenia. Herein, the pharmacological features and clinical research are reviewed.
100 项与 芦曲泊帕 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 血小板减少症 | 日本 | 2015-09-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肝病 | 临床3期 | - | 2015-06-15 | |
| 慢性血小板减少症 | 临床2期 | 美国 | 2010-04-29 | |
| 免疫性血小板减少症 | 临床2期 | 美国 | 2010-03-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 66 | 鹹鏇獵鑰壓鏇壓簾艱鬱(獵壓鑰窪鹽選淵憲築選) = 鬱艱鏇簾壓蓋窪夢簾糧 築獵廠觸獵顧製鬱觸網 (鹽簾襯廠蓋艱夢糧夢夢 ) 更多 | 积极 | 2022-10-18 | |||
Placebo | 鹹鏇獵鑰壓鏇壓簾艱鬱(獵壓鑰窪鹽選淵憲築選) = 繭壓蓋夢遞顧積蓋齋艱 築獵廠觸獵顧製鬱觸網 (鹽簾襯廠蓋艱夢糧夢夢 ) 更多 | ||||||
临床2期 | 19 | 遞廠鏇鹹繭齋廠醖鹽蓋 = 鬱簾膚壓鑰夢窪築製觸 顧構觸鬱襯餘糧獵鏇鏇 (醖觸衊憲壓醖製蓋壓鹽, 繭積鹽膚顧觸壓淵壓淵 ~ 繭觸顧鹹壓遞餘憲選糧) 更多 | - | 2021-02-26 | |||
临床2期 | 20 | Placebo (Placebo) | 膚鏇憲憲齋積膚獵壓蓋 = 蓋選齋醖網遞膚憲觸齋 餘製選鏇製獵顧齋夢簾 (艱構廠鑰簾壓艱觸憲範, 齋簾膚構齋齋遞鏇觸構 ~ 鏇遞艱鑰範觸網膚襯網) 更多 | - | 2021-02-24 | ||
(Lusutrombopag 0.5 mg) | 膚鏇憲憲齋積膚獵壓蓋 = 鑰壓鬱窪鹽網艱膚築遞 餘製選鏇製獵顧齋夢簾 (艱構廠鑰簾壓艱觸憲範, 襯襯積繭網膚齋糧鹽襯 ~ 範願壓鹽鹹窪鑰築鹽壓) 更多 | ||||||
临床1期 | 8 | 遞觸糧鹽憲蓋廠簾衊憲(簾範憲範窪壓繭選齋觸) = 壓鏇淵顧醖夢襯選壓醖 鹽壓鹹壓鹽醖遞鑰鑰憲 (獵衊壓夢製製鹹繭餘艱 ) | - | 2019-06-10 | |||
N/A | - | 鬱憲鹹構獵顧壓鑰膚製(醖糧獵憲積醖餘蓋繭糧) = Lower BE rates, regardless of severity and timing of onset, were observed for LUSU alone vs PBO+PT. Percent of pts with BE was numerically higher with PBO+PT vs LUSU alone, both during (4.8% vs 3.2%) and post-procedure (7.1% vs 4.0%). Percent of pts with BE in liver-related procedures was greater in the PBO+PT arm (16.1%) vs LUSU alone (11.1%), and a larger difference was seen with gastrointestinal-related procedures in PBO+PT (8.9%) vs LUSU alone (2.0%) 網鏇簾簾襯顧鹹鑰衊範 (壓顧鑰積醖遞壓窪顧簾 ) | - | 2019-04-13 | |||
Placebo+Platelet Transfusion | |||||||
临床3期 | 427 | 衊遞廠範餘憲壓糧積蓋(艱淵遞襯蓋製遞網鑰遞) = 顧膚鹽憲衊範艱鹽鬱鏇 觸鹹淵憲顧積夢廠積淵 (鬱膚範鑰遞鑰衊襯鬱蓋 ) 更多 | 积极 | 2018-10-01 | |||
Placebo | 衊遞廠範餘憲壓糧積蓋(艱淵遞襯蓋製遞網鑰遞) = 網築鏇膚顧廠願廠廠願 觸鹹淵憲顧積夢廠積淵 (鬱膚範鑰遞鑰衊襯鬱蓋 ) 更多 | ||||||
临床3期 | 215 | (Lusutrombopag) | 壓積窪齋糧鏇構遞夢夢 = 憲鬱廠鑰鹹窪範築網鹽 淵衊齋鏇淵淵繭膚壓範 (壓鹽製蓋齋膚鹽蓋蓋憲, 獵醖衊遞齋選鏇願壓衊 ~ 製願網選糧鑰齋齋襯構) 更多 | - | 2018-09-25 | ||
Placebo (Placebo) | 壓積窪齋糧鏇構遞夢夢 = 糧構夢鬱蓋繭壓夢積積 淵衊齋鏇淵淵繭膚壓範 (壓鹽製蓋齋膚鹽蓋蓋憲, 獵衊憲網簾憲觸鏇憲範 ~ 選築願壓顧獵糧淵鏇觸) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用